Tìm theo
Levofloxacin
Các tên gọi khác (10 ) :
  • (-)-Ofloxacin
  • (3S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
  • (S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
  • (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
  • (S)-Ofloxacin
  • L-ofloxacin
  • Levofloxacine
  • Levofloxacino
  • Levofloxacinum
  • Ofloxacin S-(-)-form
Thuốc trị ký sinh trùng, chống nhiễm khuẩn
Thuốc Gốc
Small Molecule
CAS: 100986-85-4
ATC: J01MA12, S01AE05
ĐG : Advanced Pharmaceutical Services Inc.
CTHH: C18H20FN3O4
PTK: 361.3675
A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C18H20FN3O4
Phân tử khối
361.3675
Monoisotopic mass
361.143784348
InChI
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
InChI Key
InChIKey=GSDSWSVVBLHKDQ-JTQLQIEISA-N
IUPAC Name
(2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
Traditional IUPAC Name
levofloxacin
SMILES
C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1
Độ hòa tan
Insoluble
logP
2.1
logS
-2.4
pKa (strongest acidic)
5.45
pKa (Strongest Basic)
6.2
PSA
73.32 Å2
Refractivity
94.94 m3·mol-1
Polarizability
36.69 Å3
Rotatable Bond Count
2
H Bond Acceptor Count
7
H Bond Donor Count
1
Physiological Charge
-1
Number of Rings
4
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Levofloxacin, a fluoroquinolone antiinfective, is the optically active L-isomer of ofloxacin. Levofloxacin is used to treat bacterial conjunctivitis, sinusitis, chronic bronchitis, community-acquired pneumonia and pneumonia caused by penicillin-resistant strains of Streptococcus pneumoniae, skin and skin structure infections, complicated urinary tract infections and acute pyelonephritis.
Cơ Chế Tác Dụng : A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem] Levofloxacin inhibits bacterial type II topoisomerases, topoisomerase IV and DNA gyrase. Levofloxacin, like other fluoroquinolones, inhibits the A subunits of DNA gyrase, two subunits encoded by the gyrA gene. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing; DNA replication and transcription is inhibited.
Dược Động Học :
▧ Absorption :
Absorption of ofloxacin after single or multiple doses of 200 to 400 mg is predictable, and the amount of drug absorbed increases proportionately with the dose.
▧ Protein binding :
24-38% (to plasma proteins)
▧ Metabolism :
Mainly excreted as unchanged drug (87%); undergoes limited metabolism in humans.
▧ Route of Elimination :
Mainly excreted as unchanged drug in the urine.
▧ Half Life :
6-8 hours
Độc Tính : Side effects include disorientation, dizziness, drowsiness, hot and cold flashes, nausea, slurring of speech, swelling and numbness in the face
Chỉ Định : For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.
Tương Tác Thuốc :
  • Acenocoumarol The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of acenocoumarol.
  • Aluminium Formation of non-absorbable complexes
  • Amiodarone Increased risk of cardiotoxicity and arrhythmias
  • Anisindione The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of anisindione.
  • Artemether Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Bepridil Increased risk of cardiotoxicity and arrhythmias
  • Bretylium Increased risk of cardiotoxicity and arrhythmias
  • Calcium Formation of non-absorbable complexes
  • Calcium Acetate Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as levofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.
  • Chlorpromazine Increased risk of cardiotoxicity and arrhythmias
  • Dicoumarol The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of dicumarol.
  • Dihydroquinidine barbiturate Increased risk of cardiotoxicity and arrhythmias
  • Disopyramide Increased risk of cardiotoxicity and arrhythmias
  • Erythromycin Increased risk of cardiotoxicity and arrhythmias
  • Fluphenazine Increased risk of cardiotoxicity and arrhythmias
  • Iron Formation of non-absorbable complexes
  • Iron Dextran Formation of non-absorbable complexes
  • Josamycin Increased risk of cardiotoxicity and arrhythmias
  • Lumefantrine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Magnesium Formation of non-absorbable complexes
  • Magnesium oxide Formation of non-absorbable complexes
  • Mesoridazine Increased risk of cardiotoxicity and arrhythmias
  • Methotrimeprazine Increased risk of cardiotoxicity and arrhythmias
  • Perphenazine Increased risk of cardiotoxicity and arrhythmias
  • Procainamide Levofloxacin may increase the effect of procainamide.
  • Prochlorperazine Increased risk of cardiotoxicity and arrhythmias
  • Promazine Increased risk of cardiotoxicity and arrhythmias
  • Promethazine Increased risk of cardiotoxicity and arrhythmias
  • Propiomazine Increased risk of cardiotoxicity and arrhythmias
  • Quinidine Increased risk of cardiotoxicity and arrhythmias
  • Quinidine barbiturate Increased risk of cardiotoxicity and arrhythmias
  • Quinupristin This combination presents an increased risk of toxicity
  • Sotalol Increased risk of cardiotoxicity and arrhythmias
  • Sucralfate Formation of non-absorbable complexes
  • Tacrolimus Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
  • Thiethylperazine Increased risk of cardiotoxicity and arrhythmias
  • Thioridazine Increased risk of cardiotoxicity and arrhythmias
  • Thiothixene May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
  • Toremifene Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
  • Trifluoperazine Increased risk of cardiotoxicity and arrhythmias
  • Triflupromazine Increased risk of cardiotoxicity and arrhythmias
  • Trimipramine Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
  • Voriconazole Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
  • Vorinostat Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
  • Warfarin The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of warfarin.
  • Zinc Formation of non-absorbable complexes
  • Ziprasidone Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
  • Zuclopenthixol Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Liều Lượng & Cách Dùng : Solution - Intravenous - 125 mg/5 ml
Tablet, film coated - Oral - 250 mg
Tablet, film coated - Oral - 500 mg
Tablet, film coated - Oral - 750 mg
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Cravit
  • Công ty :
    Sản phẩm biệt dược : Elequine
  • Công ty :
    Sản phẩm biệt dược : Floxel
  • Công ty :
    Sản phẩm biệt dược : Iquix
  • Công ty :
    Sản phẩm biệt dược : Leroxacin
  • Công ty :
    Sản phẩm biệt dược : Levaquin
  • Công ty :
    Sản phẩm biệt dược : Levokacin
  • Công ty :
    Sản phẩm biệt dược : Levox
  • Công ty :
    Sản phẩm biệt dược : Levoxacin
  • Công ty :
    Sản phẩm biệt dược : Mosardal
  • Công ty :
    Sản phẩm biệt dược : Nofaxin
  • Công ty :
    Sản phẩm biệt dược : Quixin
  • Công ty :
    Sản phẩm biệt dược : Reskuin
  • Công ty :
    Sản phẩm biệt dược : Tavanic
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB01137
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=149096
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505134
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C07660
ChemSpider
http://www.chemspider.com/Chemical-Structure.131410.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50167506
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/68669-135-05
PharmGKB
http://www.pharmgkb.org/drug/PA450214
Wikipedia
http://en.wikipedia.org/wiki/Levofloxacin
RxList
http://www.rxlist.com/cgi/generic2/quixin.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/flo1181.shtml
Drugs.com
http://www.drugs.com/cdi/levofloxacin-drops.html
... loading
... loading